Neuromod Devices Ltd.

About Neuromod Devices

Neuromod Devices Ltd., headquartered in Dublin, Ireland, was founded on January 1, 2010. The company focuses on addressing the clinical needs of patients with chronic and debilitating conditions through neuromodulation technologies. Its core application lies in tinnitus treatment. The Lenire system, developed by Neuromod, is the first and only FDA-approved bimodal neuromodulation tinnitus treatment device. As of 2025, the company holds over 136 neuromodulation patents across 37 countries, with more than 200 clinicians providing Lenire services in Europe and the U.S.

Core Business & Key Technologies

Neuromod Devices specializes in developing and commercializing neuroregulation technologies for tinnitus treatment. The Lenire system combines tongue electrical stimulation with customized sound therapy to activate neuroplasticity in the brain's auditory and somatosensory cortices, inhibiting abnormal neural signals and alleviating tinnitus symptoms. This dual-pathway neuroregulation technology surpasses traditional sound therapy, providing long-term efficacy. Clinical trials, including TENT-A1, TENT-A2, and TENT-A3, have demonstrated significant and sustained improvements in tinnitus symptoms among patients.

Market Position & Flagship Products

Neuromod Devices holds a leading position in the global tinnitus treatment market. The Lenire system is FDA-approved and marketed in Europe. With more than 600 patients enrolled in clinical trials, the device has shown high efficacy and long-lasting benefits. Neuromod has raised multiple funding rounds, including a $33.2 million Series B2 round in April 2025 and a €10 million Series B round in March 2025. These investments will accelerate Lenire’s commercialization, U.S. launch, and next-generation product development.

Recent Developments

In 2025, Neuromod Devices announced the completion of a $33.2 million financing round led by Panakès Partners, with participation from Fountain Healthcare Partners and venture debt from the European Investment Bank. Additional funding rounds in March and July 2025, each exceeding €10 million, further supported its expansion in Europe and the U.S. Neuromod is also exploring collaborations with the U.S. Department of Defense and Department of Veterans Affairs.

Key Personnel

Neuromod Devices was founded by Dr. Ross O'Neill, who serves as the CEO. In 2025, Alesio Beverina, Managing Partner at Panakès Partners, joined the company's board of directors to support its strategic growth.

Contact Information

• Registered Address: The Digital Hub, Unit J, Digital Court, Rainsford Street, Dublin 8, Ireland

• Email: info@neuromoddevices.com